SLC5A2 and Hyperglycemia: This novel approach to management of glucocorticoid-induced hyperglycemia has not been tested before and if SGLT2 inhibition with empagliflozin compared to NPH insulin is a safe, effective and resource sparing treatment for GIDM, it has the potential to improve the situation for affected patients.